Nuvation Bio Inc.
Clinical trials sponsored by Nuvation Bio Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for metabolic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to stop lung cancer recurrence in High-Risk patients
Disease control Recruiting nowThis phase 3 trial tests whether the drug taletrectinib can prevent non-small cell lung cancer from coming back after surgery in people with a specific genetic change (ROS1 fusion). About 180 participants will receive either taletrectinib or a placebo daily for several years. The…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New lung cancer drug aims to outperform current standard in advanced ROS1-positive patients
Disease control Recruiting nowThis study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrec…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC